Skip to main content

CERO Therapeutics Holdings, Inc.

corporate_fare Company Profile

CERO Therapeutics Holdings, Inc.

CERO·OTC·Life Sciences·CIK 0001870404

We are an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment. Our proprietary T cell engineering approach integrates characteristics of both innate and adaptive immunity into a single therapeutic construct, aiming to engage the body's full immune system for optimized cancer therapy. Our novel cellular immunotherapy platform redirects patient-derived T cells to eliminate tumors by employing both cytotoxic and phagocytic mechanisms to destroy cancer cells, creating Chimeric Engulfment Receptor T ("CER-T") cells. Our lead molecule is CER-1236, an autologous T-cell product targeting the TIM-4 ligand tumor antigen. We believe CER-1236 will be active in both hematological malignancies and solid tumors. On November 14, 2024, the FDA cleared our Investigational New Drug Application ("IND") for CER-1236 after a brief clinical hold due to insufficient nonclinical data, which was lifted following additional in vitro experiments. In May 2025, we initiated our Phase 1 clinical trial for CER-1236 in patients with acute myeloid leukemia ("AML"). This first-in-human, multi-center, open label, Phase 1/1b study evaluates the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML, AML in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. On March 27, 2025, the FDA accepted our second IND application for CER-T cell therapy in non-small cell lung cancer ("NSCLC") and ovarian cancer.

CERO Therapeutics Holdings, Inc. (OTC:CERO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for CERO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 12 most recent items scored 7 or higher, the top rating is 10/10, with 11 rated 8 or above. Recent SEC coverage for CERO spans 10-Q, 424B3, 10-K, 8-K.

Recent high-impact activity:

  • CERo 10-Q: Going Concern Doubt, $650K Cash, Pending Subsidiary Sale to SRX
  • CERO Therapeutics Files Prospectus Supplement Incorporating Dire 10-K, Revealing Ongoing Dilutive Financings and Going Concern Warning
  • CERO Therapeutics Faces Going Concern Warning Amidst Nasdaq Delisting and Highly Dilutive Financing
  • Registers 729.6M Shares for Resale from Highly Dilutive Convertible Note
  • CERO Secures $350K in Highly Dilutive Convertible Note Financing

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 20,236 shares in CERO as of the October 30, 2026 settlement, a 1911.5% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 93.6% of CERO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)20,236 shares as of October 30, 2026
Change vs prior period▲ 1911.5%
Days to cover1.00 at avg daily volume of 922,067
Daily short volume (FINRA facilities)93.6% of 155,506 shares on November 20, 2026
5-day average short volume36.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$0.0037 -6.33% today
52-week range · as of 2026-11-13 $0.0031 – $0.135
Market cap
$294.93K
Volume
155.5K (0.3× avg)
3-mo avg 491.6K
Live data · 2026-11-22 12:41 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CERO - Latest Insights

CERO
Nov 13, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.0048
Real-time Price: $0.0037 info
Change: -$0.0011 (-23%) info
Market Cap: $294.926K info
CERO
Apr 15, 2026, 4:59 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.032
Real-time Price: $0.0037 info
Change: -$0.0283 (-88%) info
Market Cap: $294.926K info
CERO
Apr 15, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.032
Real-time Price: $0.0037 info
Change: -$0.0283 (-88%) info
Market Cap: $294.926K info
CERO
Apr 14, 2026, 4:03 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.0315
Real-time Price: $0.0037 info
Change: -$0.0278 (-88%) info
Market Cap: $294.926K info
CERO
Apr 14, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.0315
Real-time Price: $0.0037 info
Change: -$0.0278 (-88%) info
Market Cap: $294.926K info
CERO
Mar 10, 2026, 7:43 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.035
Real-time Price: $0.0037 info
Change: -$0.0313 (-89%) info
Market Cap: $294.926K info
CERO
Feb 20, 2026, 4:01 PM EST
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.040
Real-time Price: $0.0037 info
Change: -$0.0363 (-91%) info
Market Cap: $294.926K info
CERO
Feb 13, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.039587
Real-time Price: $0.0037 info
Change: -$0.035887 (-91%) info
Market Cap: $294.926K info
CERO
Feb 04, 2026, 9:12 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0485
Real-time Price: $0.0037 info
Change: -$0.0448 (-92%) info
Market Cap: $294.926K info
CERO
Feb 03, 2026, 5:15 PM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.0485
Real-time Price: $0.0037 info
Change: -$0.0448 (-92%) info
Market Cap: $294.926K info
CERO
Jan 08, 2026, 4:05 PM EST
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.055065
Real-time Price: $0.0037 info
Change: -$0.051365 (-93%) info
Market Cap: $294.926K info
CERO
Jan 07, 2026, 4:37 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.055
Real-time Price: $0.0037 info
Change: -$0.0513 (-93%) info
Market Cap: $294.926K info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets